Court hears free-speech fight against off-label rules; France probes deaths linked to Servier drug;

@FiercePharma: Musty odor prompts another Lipitor recall. Story | Follow @FiercePharma

> A U.S. federal appeals court heard oral arguments in a case that presents a free-speech challenge to rules against discussion of off-label uses of a drug. Report

> A former GlaxoSmithKline lawyer charged with obstructing a regulatory review of the company wants prosecutors to disclose data on law firm King & Spalding's advice to the drugmaker during the probe. Story

> A former employee is suing Novo Nordisk for wrongly terminating his employment. Article

> Teva Pharmaceutical Industries said it has reached a deal with Japanese drugmaker Takeda Pharmaceutical that allows it to sell a generic version of Takeda's widely used diabetes drug Actos in 2012. ReleaseReport

> The French Health Ministry is investigating the deaths of possibly more than 2,000 people who developed heart valve problems after taking the Servier diabetes drug and appetite suppressant Mediator. Le Figaro reported last month that 500 people were thought to have died. Item

> A handful of House Democrats have introduced legislation that would increase funding and authority for the FDA to monitor drug production--both domestically and overseas--in hopes of improving safety. Report

> Pfizer lobbied to scupper a free trade deal between the U.S. and New Zealand because it was angry at the New Zealand government's healthcare system, which strictly controls prices and new drug approvals, according to diplomatic cables leaked by Wikileaks. Item

> For the second time this month, the AIDS Healthcare Foundation, which runs free AIDS clinics in the U.S. and other countries, has filed a lawsuit against a drugmaker for overcharging the organization for drugs purchased under the federal 340B Drug Pricing Program. Story

> Pharmaceutical distributor McKesson has won U.S. antitrust approval to buy privately held US Oncology, the Federal Trade Commission said. Article

Biotech News

@FierceBiotech:  Pfizer opts out of $262M Adolor pain drug pact. News | Follow @FierceBiotech

> Forbes columnist: Vegas rules apply to biotech investing. News 

> Arena maps out its one-year plan for lorcaserin. Article 

> ReNeuron stem cell trial clears first hurdle. Item 

> Corcept shares jump on promising PhIII data. Report 

> Vertex trims a telaprevir study from its slate of hep C work. News

Drug Delivery News

> Israeli company develops needle-free system. Story

> New gel could sweeten drug delivery. Report

> Generex granted 162nd buccal drug delivery patent. News

> Sanofi-Aventis buys rights to insulin delivery tech. Story

> Emisphere, Novo Nordisk get together on insulin pill. Article

> Gold-plated liposomes an anti-cancer stocking stuffer. Report

Medical Device News

> Boston Sci division has DoJ, IRS woes. Story 

> MagForce looks to tackle solid tumors. Article

> BG withdraws planned IPO. Report

> Boston Sci ($BSX) to get tax credit. News 

> Minn. group endorses recycling pacemakers for needy. Article

> Orthopedics maker Small Bone raises $15M. Story 

> REVA closes $63M Aussie IPO. News

> Medtronic's Hawkins out at the end of the fiscal year. Article

And Finally... Scientists have isolated a set of proteins that accounts for more than 130 brain diseases, including Alzheimer's disease, Parkinson's disease, epilepsies and forms of autism. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.